Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated <i>MGMT</i>
In this study, we evaluated the benefit on survival of the combination of methylation of O6-methylguanine-DNA methyltransferase (<i>MGMT</i>) promotor gene and moderate vascularity in glioblastoma using a retrospective dataset of 123 patients from a multicenter cohort. MRI processing and...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/21/5420 |
| _version_ | 1797512744252997632 |
|---|---|
| author | María del Mar Álvarez-Torres Elies Fuster-García Carmen Balaña Josep Puig Juan M. García-Gómez |
| author_facet | María del Mar Álvarez-Torres Elies Fuster-García Carmen Balaña Josep Puig Juan M. García-Gómez |
| author_sort | María del Mar Álvarez-Torres |
| collection | DOAJ |
| description | In this study, we evaluated the benefit on survival of the combination of methylation of O6-methylguanine-DNA methyltransferase (<i>MGMT</i>) promotor gene and moderate vascularity in glioblastoma using a retrospective dataset of 123 patients from a multicenter cohort. MRI processing and calculation of relative cerebral blood volume (rCBV), used to define moderate- and high-vascular groups, were performed with the automatic ONCOhabitats method. We assessed the previously proposed rCBV threshold (10.7) and the new calculated ones (9.1 and 9.8) to analyze the association with survival for different populations according to vascularity and <i>MGMT</i> methylation status. We found that patients included in the moderate-vascular group had longer survival when <i>MGMT</i> is methylated (significant median survival difference of 174 days, <i>p</i> = 0.0129*). However, we did not find significant differences depending on the <i>MGMT</i> methylation status for the high-vascular group (<i>p</i> = 0.9119). In addition, we investigated the combined correlation of <i>MGMT</i> methylation status and rCBV with the prognostic effect of the number of temozolomide cycles, and only significant results were found for the moderate-vascular group. In conclusion, there is a lack of benefit of extending temozolomide treatment for patients with high vascular glioblastomas, even presenting <i>MGMT</i> methylation. Preliminary results suggest that patients with moderate vascularity and methylated <i>MGMT glioblastomas</i> would benefit more from prolonged adjuvant chemotherapy. |
| first_indexed | 2024-03-10T06:06:01Z |
| format | Article |
| id | doaj.art-e03182da8c724756bdbef0356b366f8e |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T06:06:01Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-e03182da8c724756bdbef0356b366f8e2023-11-22T20:35:00ZengMDPI AGCancers2072-66942021-10-011321542010.3390/cancers13215420Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated <i>MGMT</i>María del Mar Álvarez-Torres0Elies Fuster-García1Carmen Balaña2Josep Puig3Juan M. García-Gómez4Biomedical Data Science Laboratory, Instituto Universitario de Tecnologías de la Información y Comunicaciones, Universitat Politècnica de València, 46022 Valencia, SpainBiomedical Data Science Laboratory, Instituto Universitario de Tecnologías de la Información y Comunicaciones, Universitat Politècnica de València, 46022 Valencia, SpainInstitut Catala d’Oncologia (ICO), Applied Research Group in Oncology (B-ARGO Group), Institut Investigació Germans Trias i Pujol (IGTP), 08916 Badalona, SpainInstitut de Diagnostic per la Image (IDI), Hospital Dr. Josep Trueta, 17007 Girona, SpainBiomedical Data Science Laboratory, Instituto Universitario de Tecnologías de la Información y Comunicaciones, Universitat Politècnica de València, 46022 Valencia, SpainIn this study, we evaluated the benefit on survival of the combination of methylation of O6-methylguanine-DNA methyltransferase (<i>MGMT</i>) promotor gene and moderate vascularity in glioblastoma using a retrospective dataset of 123 patients from a multicenter cohort. MRI processing and calculation of relative cerebral blood volume (rCBV), used to define moderate- and high-vascular groups, were performed with the automatic ONCOhabitats method. We assessed the previously proposed rCBV threshold (10.7) and the new calculated ones (9.1 and 9.8) to analyze the association with survival for different populations according to vascularity and <i>MGMT</i> methylation status. We found that patients included in the moderate-vascular group had longer survival when <i>MGMT</i> is methylated (significant median survival difference of 174 days, <i>p</i> = 0.0129*). However, we did not find significant differences depending on the <i>MGMT</i> methylation status for the high-vascular group (<i>p</i> = 0.9119). In addition, we investigated the combined correlation of <i>MGMT</i> methylation status and rCBV with the prognostic effect of the number of temozolomide cycles, and only significant results were found for the moderate-vascular group. In conclusion, there is a lack of benefit of extending temozolomide treatment for patients with high vascular glioblastomas, even presenting <i>MGMT</i> methylation. Preliminary results suggest that patients with moderate vascularity and methylated <i>MGMT glioblastomas</i> would benefit more from prolonged adjuvant chemotherapy.https://www.mdpi.com/2072-6694/13/21/5420glioblastoma<i>MGMT</i> methylationtumor vascularitychemotherapyadjuvant temozolomidetemozolomide cycles |
| spellingShingle | María del Mar Álvarez-Torres Elies Fuster-García Carmen Balaña Josep Puig Juan M. García-Gómez Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated <i>MGMT</i> Cancers glioblastoma <i>MGMT</i> methylation tumor vascularity chemotherapy adjuvant temozolomide temozolomide cycles |
| title | Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated <i>MGMT</i> |
| title_full | Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated <i>MGMT</i> |
| title_fullStr | Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated <i>MGMT</i> |
| title_full_unstemmed | Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated <i>MGMT</i> |
| title_short | Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated <i>MGMT</i> |
| title_sort | lack of benefit of extending temozolomide treatment in patients with high vascular glioblastoma with methylated i mgmt i |
| topic | glioblastoma <i>MGMT</i> methylation tumor vascularity chemotherapy adjuvant temozolomide temozolomide cycles |
| url | https://www.mdpi.com/2072-6694/13/21/5420 |
| work_keys_str_mv | AT mariadelmaralvareztorres lackofbenefitofextendingtemozolomidetreatmentinpatientswithhighvascularglioblastomawithmethylatedimgmti AT eliesfustergarcia lackofbenefitofextendingtemozolomidetreatmentinpatientswithhighvascularglioblastomawithmethylatedimgmti AT carmenbalana lackofbenefitofextendingtemozolomidetreatmentinpatientswithhighvascularglioblastomawithmethylatedimgmti AT joseppuig lackofbenefitofextendingtemozolomidetreatmentinpatientswithhighvascularglioblastomawithmethylatedimgmti AT juanmgarciagomez lackofbenefitofextendingtemozolomidetreatmentinpatientswithhighvascularglioblastomawithmethylatedimgmti |